Trinity Biotech announces strategic partnership with imaware

Trinity Biotech announced a strategic partnership with imaware Inc that combines their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs. Summary Highlights: Trinity Biotech will make a $1.5M convertible note investment in imaware alongside lead investor McNair Interests to accelerate partnership commercialisation efforts with a pipeline of payor sponsored digital health solutions, tele-health services, provider networks, healthcare marketplaces, retail pharmacies and pharmaceutical companies. Trinity Biotech has entered into a 5-year agreement to become the lab testing partner for imaware, starting later in 2023. Under this relationship, imaware and Trinity Biotech are targeting having over 650,000 test kits processed annually by Trinity Biotech at its advanced New York-based reference lab facility by the third year, and are planning on providing seamless follow-up confirmatory testing for imaware’s users. The partnership will focus on providing fully integrated private and white-label solutions specifically designed for the needs of digital health channel partners with industry-leading rapid-turnaround with patient centric ecosystem integration. The partners plan to evolve their offerings with user-interface innovations and the integration of lab and at-home rapid test programs leveraging Trinity Biotech’s point-of-care product development and manufacturing capabilities.